Oryza

Oryza is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative small molecule therapeutics for oncology and other life-threatening diseases. The company leverages its expertise in structure-based drug design and the RAS/MAPK signaling pathway to develop first-in-class and best-in-class medicines. Its lead candidate, ORY-101, is a potent and selective SHP2 inhibitor currently undergoing clinical evaluation for the treatment of advanced solid tumors. Oryza is headquartered in Suzhou BioBAY, China, with additional research facilities in San Diego, California. The company's pipeline also includes inhibitors targeting FGFR4 and SOS1, aimed at addressing unmet needs in precision oncology. Backed by prominent investors such as Qiming Venture Partners and Legend Capital, Oryza is positioned to advance its portfolio of targeted therapies through global clinical development.